Administration of Glutaredoxin-1 Attenuates Liver Fibrosis Caused by Aging and Non-Alcoholic Steatohepatitis

• Main Authors: Yuko Tsukahara (Author), Beatriz Ferran (Author), Erika T. Minetti (Author), Brian S. H. Chong (Author), Adam C. Gower (Author), Markus M. Bachschmid (Author), Reiko Matsui (Author)
• Format: Book
• Published: MDPI AG, 2022-04-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Liver fibrosis is a sign of non-alcoholic fatty liver disease progression towards steatohepatitis (NASH) and cirrhosis and is accelerated by aging. Glutaredoxin-1 (Glrx) controls redox signaling by reversing protein <i>S</i>-glutathionylation, induced by oxidative stress, and its deletio...